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Signiﬁcant therapeutic nihilism exists among health professionals. Recent progress has reshaped the
clinical landscape in the treatment of MPM. Two European guidelines have been published, one
from the Task force of the European Respiratory Society (ERS) and the European Society of Tho-
racic Surgery (ESTS) and the other from the European Society of Medical Oncology (ESMO). With
these guidelines and recommendations as a guidepost, this review discusses the major changes and
their impact on the management of MPM.
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In 2010, three European societies have issued either guidelines
or recommendations regarding the management of mesotheli-
oma. The European Respiratory Society and the European
Society of Thoracic Surgery formed a common task force
consisting of 18 experts of 8 disciplines and 8 countries. Based
on a set of questions formulated by those experts, a systematic138001; fax: +20 2 23664720.
R. Gaafar).
Production and hosting by
o University.
lsevierliterature review was conducted covering aspects of epidemiol-
ogy, diagnosis, staging and treatment. The evidence and the
recommendations were graded according to the grading system
of the American College of Chest Physicians (ACCP) and
voted by the experts. Finally, the manuscript was submitted
to expert external peer review by the ‘European Respiratory
Journal’, wherein it was later published [1].
The European Society of Medical Oncology (ESMO) in-
vited 4 experts from 3 disciplines and countries to write state-
ments on the staging and tumor-directed treatment, based on
an extensive literature search and using the grading of the
American Society of Clinical Oncology (ASCO). The manu-
script was peer reviewed externally by ‘Annals of Oncology’,
wherein it was published in a Guidelines supplement [2].
This article reviews the recommendations as proposed by
these scientiﬁc societies. Table 1 summarizes the most impor-
tant recommendations, their corresponding level of evidence
and displays the small differences between the two guidelines.
Treatment of MPM can be either aimed at symptom relieve
or have an intention to cure. Radical treatment is reserved for a
282 E. van Thiel et al.carefully selected subgroup of patients and this makes palliative
treatments the keystone of care for the vast majority of patients
with MPM. But regardless of the initial treatment intention,
supportive care should be offered to all patients with MPM.Treatment with palliative intent
MPM has a strong negative impact on the quality of life of the
people suffering from this disease. Although MPM can cause a
large number of complaints, its symptom management is
mainly aimed at pain relief and improving shortness of breath.
Symptom control
Patients with MPM often have troublesome symptoms signiﬁ-
cantly decreasing their quality of life. These symptoms need
addressing, regardless of the institution of active treatment.
Offering comprehensive supportive care is of paramount impor-
tance in patients withMPM, as the severe disease symptom bur-
den often causes extreme suffering for both patients and
families. The most common symptoms are shortness of breath
and pain, affecting over 90% of MPM patients. Other symp-
toms reported by MPM are tiredness (36%), worry (29%),
cough (22%), sweating (22%), and constipation (22%) [3].
The pain can originate from pleural based disease or chest
wall invasion and consists of a complex of nociceptive, neuro-
pathic, and inﬂammatory components being referred to as the
costopleural syndrome. The nociceptive pain caused by chest
wall involvement can be treated with opioids, as for the
inﬂammatory part, Non-Steroidal Anti-Inﬂammatory Drugs
(NSAID) are useful. Treatment of neuropathic pain, either dis-
ease or chemotherapy induced, includes the usual agents used
for patients with neuropathic pain from any etiology (anti-
convulsants, corticosteroids, tricyclic antidepressants, and
alpha-2 agonists) [4]. Due to the complex nature of the pain
and relatively large innervations of the chest wall and pleura,
pain with MPM is often hard to control, with pain medication
escalating rapidly on WHO analgesic ladder. For strictly
selected patients with refractory or uncontrolled pain with
analgesics, percutaneous cervical cordotomy in an experienced
center can be considered [5,6].
The cause of dyspnea is often multifactorial, including pleu-
ral ﬂuid, a trapped lung or preexisting co-morbidity and a
number of treatment modalities may be required to address
this symptom. Pleurodesis is useful in preventing recurrent
effusions and repeated thoracentesis can be avoided if pleurod-
esis is performed early in the disease process before the effu-
sion has become loculated and/or the lung ﬁxed and unable
to expand fully. For a successful pleurodesis, pleural sheets
need to be approximated and sterile talc is the most effective
chemical sclerosant, but no signiﬁcant differences between a
medical or a thoracoscopic procedure have been demon-
strated. It is of paramount importance that sufﬁcient tissue
for the diagnosis of MPM has been obtained before perform-
ing a pleurodesis [7].
For very frail patients, however, repeated aspiration may
still be the most practical way to manage recurrent effusions,
or alternatively an indwelling chest drain can be placed. Other
strategies include pleurectomy/decortication for patients with
a trapped lung syndrome and failure of pleurodesis as dis-
cussed in the following paragraph.Independent of the cause, low-dose oral morphine may be
useful in reducing the dyspnea sensation and the accompany-
ing anxiety. Oxygen can be helpful but should not be used un-
less there is evidence of reduced oxygen [8].
Debulking pleurectomy/decortication
Debulking pleurectomy/decortication can be deﬁned as signif-
icant but incomplete macroscopic clearance of pleural tumor.
The objective of the operation is to relieve an entrapped lung
by removing the visceral tumor cortex. Subtotal parietal pleur-
ectomy provides a lasting and effective pleurodesis and gives
the opportunity to obtain large volumes of tissue in cases of
difﬁcult histological diagnosis. Removal of the parietal tumor
cortex may also relieve a restrictive ventilatory defect and re-
duce chest wall pain. Unfortunately when performed through
a thoracotomy it has been associated with signiﬁcant morbid-
ity [9,10]. However, there is emerging evidence that the use of
Video Assisted Thoracic Surgery (VATS) pleurectomy is able
to give symptom control with lower morbidity and may even
have an effect on survival [11]. It can be considered in symp-
tomatic patients with entrapped lung syndrome who cannot
beneﬁt from chemical pleurodesis and with an expected sur-
vival of more than 6 months. No randomized trials have been
conducted, but there is an ongoing trial in the UK comparing
VATS debulking with chemical pleurodesis.
Palliative radiotherapy
Palliative radiotherapy aimed at pain relief can be considered
in cases of painful chest wall inﬁltration or nodules [12]. The
initial effect is often encouraging, but responses are unfortu-
nately generally only short lived [13]. Combining radiotherapy
and hyperthermia resulted in higher response rate for those
receiving additional hyperthermia [14]. Further validation of
this cumbersome technique is needed before its routine use
can be advised. Hyperthermia is currently limited to a few spe-
cialized centers.
Prophylactic radiotherapy
The diagnosis of MPM is often established by invasive proce-
dures. Regardless of the procedure used, tumor cell seeding
leading to metastases at the biopsy sites occurs in up to 20%
of the patients. Prevention of malignant seeding with prophy-
lactic radiotherapy along the tracts of these procedures has
therefore received much attention. Randomized trials showed
contradictory evidence; the results of three trials have been
pooled in a recent meta-analysis which showed no signiﬁcant
reduction of the relative risk of the occurrence of tract metas-
tasis [15]. The discrepancies between these results may be
partly attributed to different techniques of radiotherapy and
the emergence of effective systemic therapies delaying the
occurrence of tract metastases. Because of these conﬂicting
data and the availability of adequate systemic therapies and
palliative radiation schemes in case of tract seeding, the value
of prophylactic radiotherapy is questionable.
Palliative chemotherapy
There have been important recent developments in the use of
chemotherapy for mesothelioma. The largest randomized trial
Table 1 Management of MPM. Recommendations from the ESMO and ERS/ESTS guidelines, with corresponding level of evidence.
Adapted from [1,2].
ESMO Levela ERS-ESTS Levelb
Symptom control
Palliative local procedures to
control pleural eﬀusions
includes parietal pleurectomy
or talk pleurodesis
NA Every patient should be oﬀered supportive care.
Pleurectomy/decortication should not be
proposed in a curative intent but can be
considered in patients to obtain symptom control,
especially symptomatic patients with entrapped
lung syndrome who cannot beneﬁt from chemical
pleurodesis
2C
Palliative radiotherapy
Radiotherapy can be
delivered locally in view of
pain control or prevention of
obstructive symptoms
IV C Palliative radiotherapy aimed at pain relief may be
considered in cases of painful chest wall
inﬁltration or nodules
2C
Prophylactic irradiation of tracks
Impossible to draw deﬁnitive
conclusions regarding its
eﬃcacy
II C Its value is questionable NA
First-line chemotherapy
Platinum analogues,
doxorubicin and some
antimetabolites
(methotrexate, raltitrexed,
pemetrexed) have shown
modest single-agent activity
III B When a decision is made to treat patients with
chemotherapy, subjects in a good performance
status (PS > 60% on the Karnofsky scale or <3
on the ECOG scale) should be treated with ﬁrst-
line combination chemotherapy consisting of
platinum and pemetrexed or raltitrexed
1B
The combinations of both
pemetrexed/cisplatin, and to
a smaller extent raltitrexed/
cisplatin, have been shown to
improve survival as well as
lung function and symptom
control, in comparison with
cisplatin alone in randomized
trials
II A Alternatively, patients could be included in ﬁrst
and second line clinical trials
NA
Administration of chemotherapy should not be
delayed and should be considered before the
appearance of functional clinical signs
1C
The combination of
pemetrexed/carboplatin is an
alternative eﬀective therapy
IIIA Chemotherapy should be stopped in case of
progressive disease, grade 3–4 toxicities, or
cumulative toxic doses, or following up to six
cycles in patients who respond or are stable
1A
2C
Second line chemotherapy
Pemetrexed naı¨ve patients:
pemetrexed
NA Patients demonstrating prolonged symptomatic
and objective response with ﬁrst-line
chemotherapy may be treated again with the same
regimen in the event of recurrence
2C
Patients demonstrating
prolonged symptomatic and
objective response with ﬁrst-
line chemotherapy may be
treated again with the same
regimen in the event of
recurrence
IIC Inclusion of the patients in clinical trials is
encouraged
2C
Otherwise: Vinorelbine IIIA
Inclusion of the patients in
clinical trials is encouraged
IIC
(continued on next page)
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Table 1 (continued)
ESMO Levela ERS-ESTS Levelb
Radical surgery
Surgery, the appropriateness
of which is still under
consideration, should only be
performed on selected
patients by experienced
thoracic surgeons in the
context of a multidisciplinary
team and preferably as part
of a clinical trial
IIIA Radical surgery (EPP) should be performed only
in clinical trials, in specialized centers, as a part of
multimodal treatment
NA
PORT
Caution must be exercised
regarding the exposure of the
contralateral lung to low-
dose irradiation, especially
when using IMRT
IIIB PORT should not be performed after pleurectomy
or decortication
1A
PORT after EPP should only be proposed in
clinical trials, in specialized centres, as a part of
multimodalı`ty treatment
1A
Multimodality treatment including chemotherapy
If extrapleural
pneumonectomy is planned,
platinum-based neoadjuvant
or adjuvant combination
chemotherapy should be
considered
NA Patients who are considered candidates for this
multimodaityl approach should be included in
prospective randomised trials in experienced
centers
NA
NA: not available.
a Level of evidence. American Society of Clinical Oncology (ASCO) grading system [51].
b Level of evidence. American College of Chest Physicians (ACCP) grading system [52].
284 E. van Thiel et al.of chemotherapy in MPM to date compared a combination of
pemetrexed, a multi-targeted anti-folate, and cisplatin with cis-
platin alone in 456 patients. Median survival with the pemetr-
exed and cisplatin combination was 12.1 months, signiﬁcantly
longer than the 9.3 months with cisplatin alone. In vitamin
supplemented patients there was signiﬁcant lower hematologi-
cal toxicity. Partly because of this trial vitamin B12 and folate
supplementation were introduced in pemetrexed therapy.
Symptom relief was also better with the pemetrexed containing
therapy, although no full quality of life data have been pub-
lished [16].
Similar results were achieved in a randomized trial compar-
ing raltitrexed, another anti-folate, plus cisplatin with cisplatin
alone in 250 patients [17]. Further studies with pemetrexed
have shown that similar results may be obtained by combining
it with carboplatin rather than cisplatin, with reduced toxicity
and greater convenience of administration [28]. Only one 3-
armed randomized study was initiated in the UK that com-
pared the efﬁcacy of two different chemotherapy regimens –
one platinum combination and one single agent 3rd generation
drug – with best supportive care [3].
No studies have compared different combination chemo-
therapy regimens with each other. In the light of the still lim-
ited evidence of efﬁcacy of chemotherapy, the decision to
administer chemotherapy should be discussed with the patients
and their relatives on a case-by-case basis, like all other palli-
ative treatment modalities. When a decision is made to treat
patients with chemotherapy, subjects in a good performance
status (PS > 60% on the Karnofsky scale or <2 on theWHO scale) should be treated with ﬁrst-line combination che-
motherapy consisting of platinum analogue and an anti-folate
(pemetrexed or raltitrexed).
Other cisplatin-based combinations have been tested in
phase II studies and a meta-analysis showed promising re-
sponse rates of approximately 25–30% [29,30], Table 2. There
is hence likely to be equipoise between these regimens. While
some single agents have shown modest activity in patients with
MPM, they should not be considered as the standard of care
for ﬁrst-line treatment [30].
There is uncertainty regarding the optimal timing of chemo-
therapy. There is a common tendency to defer treatment while
the patient feels relatively well after initial effective management
of a pleural effusion by pleurodesis. The drawback is that the
transition from ‘toowell for chemotherapy’ to ‘too ill for chemo-
therapy’ can be unexpectedly rapid; so many patients miss the
opportunity to beneﬁt from chemotherapy. A small randomized
study found a survival advantage for early rather than delayed
chemotherapy without reaching statistical signiﬁcance [31].
There is also limited evidence for better efﬁcacy of chemother-
apy on small tumor volumes [32]. Administration of chemother-
apy should therefore not be delayed and should be considered
even before the appearance of functional clinical signs.
The optimal duration of chemotherapy is also controver-
sial, the scanty evidence available shows at the moment no
signiﬁcant beneﬁt for more then six cycles of chemotherapy.
So chemotherapy should be stopped in case of progressive dis-
ease, grade 3–4 toxicities or cumulative toxic doses, or after six
cycles in non-progressive patients.
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or after ﬁrst-line treatment. Second-line therapies are being
increasingly used in the clinical practice because patients fre-
quently still have good performance scores at the time of
disease progression. In pemetrexed-naı¨ve patients, data from
a randomized trial vs. best supportive care suggest the use
of single-agent pemetrexed as a standard second-line treat-
ment [33]. In a phase III study, patients with progressive
disease were randomized to best supportive care (BSC) or
second-line pemetrexed single agent. Time to progression
was signiﬁcantly longer in the pemetrexed arm but there
was no improvement in overall survival. This might be
due to signiﬁcantly more patients in the BSC arm receiving
post-discontinuation chemotherapy with pemetrexed com-
pared with patients randomized in the pemetrexed arm
[34]. To date, there is still no standard approach for the
growing population of pemetrexed-pre-treated patients. In
selected cases with a prolonged response to ﬁrst-line pemetr-
exed-based chemotherapy, re-treatment with a pemetrexed-
based regimen should be considered. When a trial is not
available or patients are not eligible for an experimental ap-
proach, single-agent vinorelbine can be a reasonable option
for palliation. However, the role of these treatments in
MPM is unproven, and the optimal regimens still remain
to be deﬁned. This makes second-line therapy in MPM an
ideal ﬁeld in which to test new chemotherapy agents as well
as new therapeutic strategies. Recommendations: Patients
demonstrating prolonged symptomatic and objective re-
sponse with ﬁrst-line chemotherapy may be treated again
with the same regimen in the event of recurrence. Pemetr-
exed-naı¨ve patients may be treated with pemetrexed, in
other cases inclusion of the patients in clinical trials is
encouraged.
Despite a number of signaling pathways being disregulat-
ed in MPM, to date targeted therapeutic agents have disap-
pointing effects in the treatment of MPM. Agents aimed at
the inhibition of speciﬁc targets, such as angiogenesis, epider-
mal growth factor receptor, histone deacetylase, and ribonu-
cleases have failed to induce substantial responses.
Immunomodulating agents, targeted biotherapies and vac-
cines should therefore not be used in the treatment of
MPM outside clinical trials. There are multiple on-going clin-
ical trials focussing on targeted therapy and a large phase III
trial to determine the effectiveness of vorinostat, a histone
deacetylase inhibitor, is about to be completed.
For assessment and follow-up of MPM a chest CT scan is
recommended. In addition to CT, contrast-enhanced MRI as
another anatomic imaging method has also been evaluated
and found to give comparable results to CT [35]. Recently,
metabolic 18 FDG-PET-imaging has been proposed as a
promising alternative for response evaluation in MPM
[36,37]. If a patient has had pleurodesis, a chest CT scan
should be performed again before the start of chemotherapy
in order to better evaluate the response to treatment.
The growth pattern of MPM provides a challenge to mea-
sure response to chemotherapy and standard response crite-
ria have been felt to be inadequate for response evaluation.
However modiﬁed Response Criteria In Solid Tumors (RE-
CIST) for MPM have been proposed by Byrne and Nowak
based on two CT-measurements of tumor thickness perpen-
dicular to the chest wall at three different levels and have be-
come widely accepted [38].
286 E. van Thiel et al.Treatment with radical intent
Surgery
Radical surgery is illustrated by extrapleural pneumonectomy
(EPP), which involves en bloc removal of tissues in the hemi-
thorax (including the pleura, lung, mediastinal lymph nodes,
diaphragm and pericardium) in order to remove all gross dis-
ease. In experienced centers, the mortality rates with EPP have
decreased to around 4%, however morbidity remains signiﬁ-
cant [39]. The role of EPP in the management of MPM re-
mains controversial due to the lack of randomized evidence
and because the eradication of all microscopic disease is theo-
retically unattainable. MPM is a diffuse disease, affecting the
entire mesothelial lining of the hemithorax, so surgery alone
will only rarely achieve adequate microscopically tumor free
resection margins. Despite a radical surgical approach, EPP
as a single modality frequently cannot prevent local recur-
rences. A retrospective analysis of 36 patients referred for rad-
ical surgery demonstrated a comparable median survival for
patients that underwent EPP and non-EPP patients (20.4 vs.
20.7 months).However the only longtime survivors with
MPM are those that underwent an EPP as part of their treat-
ment. Radical surgery (EPP) should be limited to clinical trials,
in specialized centers and as part of a multimodality treatment
[40].
Radiotherapy
Radical radiotherapy is limited by the same characteristic of
MPM that radical surgery faces, the widespread nature of the
tumor. Radiation therapy to the full hemithorax affects many
organs at risk of radiation damage, such as the lung, the li-
ver, and heart most particularly, but also the spinal cord
and esophagus. Therefore it is difﬁcult to administer a radical
dosage and even if a potentially curative schedule can be gi-
ven, no survival beneﬁt has yet been demonstrated when
comparing radical radiation of the hemithorax to best sup-
portive care [12,41]. Conventional radical radiotherapy does
however result in signiﬁcant toxicity, including radiation in-
duced pneumonitis, ﬁbrosis, and ﬁstula. Thus conventional
radical radiotherapy is limited by the large radiation ﬁelds,
failed to show a survival beneﬁt, and can presently not be
recommended as single modality treatment in a curative
setting.
Multimodality treatment
The failure of single modality treatments with an intention to
cure, to induce cure or even signiﬁcant prolongation of overall
survival has led to the interest in multimodality treatments.
The main multimodality strategies are surgery and post-oper-
ative radiotherapy (PORT) with or without chemotherapy.
Long term survival has been described in carefully selected pa-
tients with locoregional extension of MPM who receive these
aggressive multimodality strategies [42].
Surgery and PORT
PORT can be given after a pleurectomy or EPP. Retrospective
studies demonstrated similar survival data in patients receiving
pleurectomy whether or not it was followed by PORT and theaddition of conventional radiotherapy only resulted in added
morbidity (28% grade III–IV toxicity) [43]. For this reason
curative radiotherapy should not be performed after pleurec-
tomy or decortication.
Although the removal of the ipsilateral lung during EPP
eliminates the lung from the radiation treatment ﬁeld, the com-
plex target volume of the post-operative hemithorax remains a
serious challenge for PORT. Phase II trials including PORT
after EPP showed varying results with vast differences in local
and systemic recurrences, most likely reﬂecting different radia-
tion techniques and the dosages administered [44,45]. No
phase III randomized trials of PORT post-EPP exist, but a
randomized multicenter European study is ongoing (SAKK
study).
In the absence of robust evidence of the efﬁcacy of adjuvant
PORT after EPP, at the moment it only should be proposed in
clinical trials, in specialized centers and as a part of a multim-
odality treatment.
Intensity modulated radiotherapy (IMRT)
IMRT is a mode of radiotherapy that theoretically combines
good local control with protection of organs at risk [45]. Initial
studies have shown IMRT after EPP to be feasible; however
some centers reported severe pulmonary toxicity with IMRT
with up to 46% of patients developing fatal radiation pneumo-
nitis [46]. The V20 for the contralateral lung was the only inde-
pendent determinant for risk of pulmonary-related death,
implying that the V20 should be kept as low as possible after
EPP. The potentially serious adverse effects restrict IMRT
presently to expert centers.
Trimodality treatment
The most aggressive multimodality treatment with curative
intent for MPM consists presently of the sequential combina-
tion of three modalities: chemotherapy, surgery and PORT,
with PORT and surgery primarily aimed at achieving locore-
gional control and chemotherapy at preventing systemic dis-
ease. Recent phase II trials have shown a median survival
of 29 months for patients who completed trimodality treat-
ment [47,48]. This approach, however, is not tested in a mul-
ti-center fashion and a small retrospective study failed to
show any beneﬁt of combining chemotherapy and PORT
with EPP versus EPP alone [12]. In a phase II EORTC trial,
chemotherapy in the form of 3 cycles of pemetrexed and cis-
platin was followed by EPP and PORT in non progressing
patients. (79%) patients received surgery and (74%) had
EPP with a 90-day mortality of 6.5%. PORT was completed
in (65%) patients. Median overall survival time for all in-
cluded patients was 18.4 months (95% CI 15.6–32.9) and
median progression-free survival was 13.9 months (95% CI
10.9–17.2) [49]. These trimodality treatments are also very
challenging with considerable morbidity and even mortality,
for a large part caused by the inclusion of surgery (EPP).Even
after a strict selection only a minority of patients can ﬁnish all
three modalities, with failure of treatment being either iatro-
genic or disease related. In conclusion the data available on
trimodality treatment is limited and weak. Until data become
available of prospective multicenter randomized trials, pa-
tients who are considered candidates for this multimodality
approach should be included in these trials in specialized
centers.
European guidelines for the management of malignant pleural mesothelioma 287Patient selection for multimodality treatment
Multimodality treatment is feasible, but strict patient selection
is mandatory. To aid this patient selection the following crite-
ria are proposed:
1) biopsy proven MPM of non-sarcomatoid cell type
2) clinical and/or pathological stage T1-3, N0-1, M0 (some
centers include patients with N2 disease)
3) ﬁt for pneumonectomy by virtue of sufﬁcient respiratory
reserve
4) absence of other (moderately) severe co-morbidity, espe-
cially cardiovascular;
5) ﬁt to receive neoadjuvant/adjuvant chemotherapy;
6) ﬁt to receive adjuvant radical hemithorax irradiation
Conclusion
The ERS-ESTS and ESMO guidelines are a ﬁrst step in har-
monizing the management of pleural mesothelioma in Eur-
ope. They cover a broad spectrum of issues and are
multidisciplinary. Transparency and representation can cer-
tainly be improved, as well as the use of a uniform grading
system. Compared to the recently published NCCN clinical
practice guideline, they are more evidence-base, moderate,
and less aggressive [50]. As is the case of every guideline,
the implementation will be the Achilles’ heel and indicators
of the latter will have to be developed. Furthermore, the ad-
vances in management should be regularly assessed and
incorporated, calling for a periodic revision of the recommen-
dations. This revision should preferably be conducted by rep-
resentative experts appointed by all involved scientiﬁc
societies and result in true multidisciplinary guidelines. The
issues addressed should pop up by a broad survey of the ac-
tual people at the patient’s bed (bottom up) instead of im-
posed by a few experts. Finally, the guidelines will have to
be translated and distributed in different languages in order
to reach the practitioner. The costs associated with this exer-
cise should not be underestimated.
Key notes
Every patient with MPM should receive at least best support-
ive care.
In the light of limited evidence of efﬁcacy of chemotherapy,
the decision to administer chemotherapy should be discussed
with the patients and their relatives on a case-by-case basis,
like all other treatment modalities without curative purposes.
When a decision is made to treat patients with chemother-
apy, subjects in a good performance status should be treated
with ﬁrst-line combination chemotherapy consisting of plati-
num and pemetrexed or raltitrexed.
Pleurodesis is useful in preventing recurrent effusions. Ster-
ile talc is preferred to other agents and pleurodesis is most
effective when performed early in the disease process but it
should not be performed before sufﬁcient tissue for diagnosis
has been obtained.
Carefully selected patients can be offered a potentially cura-
tive multimodality approach, but no clear survival beneﬁt has
yet been demonstrated and suitable patients should be in-
cluded in prospective randomized trials in specialized centers.References
[1] Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de
Vuyst P, et al. Guidelines of the European Respiratory Society
and the European Society of Thoracic Surgeons for the
management of malignant pleural mesothelioma. Eur Respir J
2010;35:479–95.
[2] Stahel RA, Weder W, Felip E, ESMO Guidelines Working
Group. Malignant pleural mesothelioma: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann
Oncol 2009;20:73–5.
[3] Muers MF, Shephens RJ, Fisher P, Darlison L, Higgs CM,
Lowry E, et al. Active symptom with or without chemotherapy
in the treatment of patients with malignant pleural
mesothelioma (MS01): a multicentre randomized trial. Lancet
2008;371:1685–94.
[4] Abrahm JL. Palliative care for the patient with mesothelioma.
Semin Thorac Cardiovasc Surg 2009;21:164–71.
[5] Stuart G, Cramond T. Role of percutaneous cervical cordotomy
for pain of malignant origin. Med J Aust 1993;158:667–70.
[6] Jackson MB, Pounder D, Price C, Matthews AW, Neville E.
Percutaneous cervical cordotomy for the control of pain in
patients with pleural mesothelioma. Thorax 1999;54:238–41.
[7] Shaw PH, Agarwal R. Pleurodesis for malignant pleural
effusions. Cochrane Database Syst Rev 2004;CD002916.
[8] Currow DC, Smith J, Abernethy AP. Does palliative home
oxygen improve dyspnoea? A consecutive cohort study. Palliat
Med 2009;23:309–16.
[9] Martini N, Bains MS, Beattie EJ. Indications for pleurectomy in
malignant effusion. Cancer 1975;35:734–8.
[10] Martin-Ucar AE, Edwards JG, Rengajaran A, Muller S, Waller
DA. Palliative surgical debulking in malignant mesothelioma.
Predictors of survival and symptom control. Eur J Cardiothorac
Surg 2001;20:1117–21.
[11] Halstead JC, Lim E, Venkateswaran RM, Charman SC,
Goddard M, Ritchie AJ. Improved survival with VATS
pleurectomy-decortication in advanced malignant
mesothelioma. Eur J Surg Oncol 2005;31:314–20.
[12] Gordon W, Antman KH, Greenberger JS, Weichselbaum RR,
Chaffey JT. Radiation therapy in the management of patients
with mesothelioma. Int J Radiat Oncol Biol Phys 1982;8:19–25.
[13] Bissett D, Macbeth FR, Cram I. The role of palliative
radiotherapy in malignant mesothelioma. Clin Oncol (R
CollRadiol) 1991;3:315–7.
[14] Ball DL, Cruickshank DG. The treatment of malignant
mesothelioma of the pleura: review of a 5-year experience,
with special reference to radiotherapy. Am J Clin Oncol
1990;13:4–9.
[15] Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans
WK. The role of radiation therapy in malignant pleural
mesothelioma: a systematic review.RadiotherOncol 2006;80:3–8.
[16] VogelzangNJ, Rusthoven JJ, Symanowski J, DenhamC, Kaukel
E, Rufﬁe P, et al. Phase III study of pemetrexed incombination
with cisplatin versus cisplatin alone in patients with malignant
pleural mesothelioma. J Clin Oncol 2003;21:2636–44.
[17] Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ,
Van Marck EA, Vincent M, et al. A randomized phase III study
of cisplatin with or without raltitrexed in patients with
malignant pleural mesothelioma: an intergroup study of the
European Organisation for Research and Treatment of Cancer
Lung Cancer Group and the National Cancer Institute of
Canada. J Clin Oncol 2005;23:6881–9.
[18] Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross
HJ, et al. Single-arm, open label study of pemetrexed plus
cisplatin in chemotherapy naı¨ve patients with malignant pleural
mesothelioma: outcomes of an expanded access program. Lung
Cancer 2007;55:187–94.
288 E. van Thiel et al.[19] Santoro A, O’Brien ME, Stahel R, Nackaerts K, Baas P, Paz-
Ares L, et al. Pemetrexed plus cisplatin (P+Cis) or pemetrexed
plus carboplatin (P+Cb) for chemonaive patients (pts) with
malignant (MPM): results of the International Expanded Access
Program (EAP). Proc ASCO 2007;26:7662.
[20] Favaretto AG, Aversa SM, Paccagnella A, Manzini VP,
Palmisano V, Oniga F, et al. Gemcitabine combined with
carboplatin in patients with malignant pleural mesothelioma.
A multicentric phase II study. Cancer 2003;97:2791–7.
[21] Hillerdal G, Sorensen JB, Sundstro¨m S, Riska H, Vikstro¨m A,
Hjerpe A. Treatment of malignant pleural mesothelioma with
carboplatin, liposomized doxorubicin, and gemcitabine: a phase
II study. J Thorac Oncol 2008;3(11):1325–31.
[22] Sorensen JB. Phase II Study of carboplatin and vinorelbine i.v.
(Day 1) and orally (Day 8) for malignant pleural mesothelioma.
ClinicalTrials.gov Identiﬁer: NCT00272558; 2010.
[23] Berghmans T, Laﬁtte JJ, Paesmans M, Stach B, Berchier MC,
Wackenier P, et al. A phase II study evaluating the cisplatin and
epirubicin combination in patients with unresectable malignant
pleural mesothelioma. Cancer 2005;50:75–82.
[24] Andreopoulou E, Ross PJ, O’Brien MER, Ford HER, Priest K,
Eisen T. The palliative beneﬁts of MVP (mitomycin C,
vinblastine and cisplatin) chemotherapy in patients with
malignant mesothelioma. Ann Oncol 2004;15:1406–12.
[25] Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G,
Buck M, et al. Cisplatin and gemcitabine treatment for
malignant pleural mesothelioma: a phase II study. J Clin
Oncol 1999;17:25–30.
[26] van Haarst JMW, Baas P, Manegold C, Schouwink JH, Burgers
JA, de Bruin HG, et al. Multicentre phase II study of
gemcitabine and cisplatin in malignant pleural mesothelioma.
Br J Cancer 2002;86:342–5.
[27] Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine
ﬁrst-line chemotherapy in non-resectable malignant pleural
mesothelioma. Br J Cancer 2008;99:44–50.
[28] Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del
Conte G, et al. Phase II study of pemetrexed plus carboplatin in
malignant pleural mesothelioma. J Clin Oncol 2006;24:1443–8.
[29] Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S,
Mascaux C, et al. Activity of chemotherapy and immunotherapy
on malignant mesothelioma: a systematic review of the literature
with meta-analysis. Lung Cancer 2002;38:111–21.
[30] Sørensen JB. Current concepts in chemotherapy for malignant
pleural mesothelioma. Clin Respir J 2008;2:74–9.
[31] O’Brien ME, Watkins D, Ryan C, Priest K, Corbishley C,
Norton A, et al. A randomised trial in malignant mesothelioma
(M) of early (E) versus delayed (D) chemotherapy in
symptomatically stable patients: the MED trial. Ann Oncol
2006;17:270–5.
[32] DeVita Jr VT. The James Ewing lecture. The relationship
between tumor mass and resistance to chemotherapy.
Implications for surgical adjuvant treatment of cancer. Cancer
1983;51:1209–20.
[33] Sørensen B, Sundstrom S, Perell K, Thielsen AK. Pemetrexed as
second-line treatment in malignant pleural mesothelioma after
platinum-based ﬁrst-line treatment. J Thorac Oncol
2007;2:147–52.
[34] JassemJ,RamlauR,SantoroA,et al. Phase III trialofpemetrexed
plus best supportive care compared with best supportive care in
previously treated patients with advanced malignant pleural
mesothelioma. J Clin Oncol 2008;26(10):1698–704.
[35] PlathowC,KloppM,ThiekeC,HerthF, ThomasA, SchmaehlA,
et al. Therapy response in malignant pleural mesothelioma-role
of MRI using RECIST, modiﬁed RECIST and volumetric
approaches in comparisonwith CT. EurRadiol 2008;18:1635–43.
[36] Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak
AK, Phillips M, et al. Early prediction of response to
chemotherapy and survival in malignant pleural mesotheliomausing a novel semiautomated 3-dimensional volume-based
analysis of serial 18F-FDG PET scans. J Nucl Med
2007;48:1449–58.
[37] Veit-Haibacha P, Schaefera N, Steinert H, Soyka JD, Seifert B,
Stahel RA. Combined FDG-PET/CT in response evaluation of
malignant pleural mesothelioma. Lung Cancer 2010;67:311–7.
[38] Byrne MJ, Nowak AK. Modiﬁed RECIST criteria for
assessment of response in malignant pleural mesothelioma.
Ann Oncol 2004;15:257–60.
[39] Sugarbaker D, Jaklitsch M, Bueno R, Richards W, Lukanich J,
Mentzer SJ, et al. Prevention, early detection and management
of complications after 328 consecutive extrapleural
pneumonectomies. J Thorac Cardiovasc Surg 2004;128:138–46.
[40] Hasani A, Alvarez JM, Wyatt JM, Bydder S, Millward M,
Byrne M, et al. Outcome for patients with malignant pleural
mesothelioma referred for trimodality therapy in Western
Australia. J Thorac Oncol 2009:1010–6.
[41] Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der
Merwe CA. Malignant pleural mesothelioma: a disease
unaffected by current therapeutic maneuvers. J Clin Oncol
1988;6:527–35.
[42] Sugarbaker DJ, Garcia JP, Richards WG, Harpole Jr DH,
Healy-Baldini E, DeCamp Jr MM, et al. Extrapleural
pneumonectomy in the multimodality therapy of malignant
pleural mesothelioma. Results in 120 consecutive patients. Ann
Surg 1996;224:288–94.
[43] Gupta V, Mychalczak B, Krug L, Flores R, Bains M, Rusch
VW, et al. Hemithoracic radiation therapy after pleurectomy/
decortication for malignant pleural mesothelioma. Int J Radiat
Oncol Biol Phys 2005;63:1045–52.
[44] Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A,
Harrison L, et al. A phase II trial of surgical resection and
adjuvant high-dose hemithoracic radiation for malignant pleural
mesothelioma. J Thorac Cardiovasc Surg 2001;122:788–95.
[45] Baldini EH. External beam radiation therapy for the treatment
of pleural mesothelioma. Thorac Surg Clin 2004;14:543–8.
[46] Allen AM, Czerminska M, Janne PA, Sugarbaker DJ, Bueno R,
Harris JR, et al. Fatal pneumonitis associated with intensity-
modulated radiation therapy for mesothelioma. Int J Radiat
Oncol Biol Phys 2006;65:640–5.
[47] Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ,
Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant
pemetrexed plus cisplatin followed by extrapleural
pneumonectomy and radiation for malignant pleural
mesothelioma. J Clin Oncol 2009;27:3007–13.
[48] Bo¨lu¨kbas S, Manegold C, Eberlein M. Survival after trimodality
therapy for malignant pleural mesothelioma: radical
pleurectomy, chemotherapy with cisplatin/permetrexed and
radiotherapy. J Lung Cancer 2009;16:24–35.
[49] Van Schil P, Baas P, Gaafar R, Maat A, Van de Pol M, Hasan
B, et al. Eur Respir J 2010;36:1362–9.
[50] NCCN mesothelioma panel. NCCN clinical practice guidelines.
Malignant Pleural Mesothelioma. <www.nccn.org> 2010.
Version 1.2010.
[51] Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D,
Hylek EM, Phillips B, et al. Grading strength of
recommendations and quality of evidence in clinical guidelines:
report from an American College Of Chest Physicians task
force. Chest 2006;129:174–81.
[52] Gralla RJ, Osoba D, Kris MJ, Kirkbride P, Hesketh PJ,
Chinnery LW, et al. Recommendations for the use of
antiemetics: evidence-based, clinical practice guidelines. J Clin
Oncol 1999;17:2971–94.
[53] Van Meerbeeck JP, Surmont VF, Scherpereel A, Baas P.
Malignant pleural mesothelioma: the standard of care and
challenges for future management. Crit Rev Oncol Hematol
2011;78:92–111.
